Psychostimulant Effect of the Synthetic Cannabinoid JWH-018 and AKB48: Behavioral, Neurochemical, and Dopamine Transporter Scan Imaging Studies in Mice

JWH-018 and AKB48 are two synthetic cannabinoids (SCBs) belonging to different structural classes and illegally marketed as incense, herbal preparations, or chemical supply for theirs psychoactive cannabis-like effects. Clinical reports from emergency room reported psychomotor agitation as one of the most frequent effects in people assuming SCBs. This study aimed to investigate the psychostimulant properties of JWH-018 and AKB48 in male CD-1 mice and to compare their behavioral and biochemical effects with those caused by cocaine and amphetamine. In vivo studies showed that JWH-018 and AKB48, as cocaine and amphetamine, facilitated spontaneous locomotion in mice. These effects were prevented by CB1 receptor blockade and dopamine (DA) D1/5 and D2/3 receptors inhibition. SPECT-CT studies on dopamine transporter (DAT) revealed that, as cocaine and amphetamine, JWH-018 and AKB48 decreased the [123I]-FP-CIT binding in the mouse striatum. Conversely, in vitro competition binding studies revealed that, unlike cocaine and amphetamine, JWH-018 and AKB48 did not bind to mouse or human DAT. Moreover, microdialysis studies showed that the systemic administration of JWH-018, AKB48, cocaine, and amphetamine stimulated DA release in the nucleus accumbens (NAc) shell of freely moving mice. Finally, unlike amphetamine and cocaine, JWH-018 and AKB48 did not induce any changes on spontaneous [3H]-DA efflux from murine striatal synaptosomes. The present results suggest that SCBs facilitate striatal DA release possibly with different mechanisms than cocaine and amphetamine. Furthermore, they demonstrate, for the first time, that JWH-018 and AKB48 induce a psychostimulant effect in mice possibly by increasing NAc DA release. These data, according to clinical reports, outline the potential psychostimulant action of SCBs highlighting their possible danger to human health.

[1]  N. Volkow,et al.  Neurocircuitry of Addiction , 2010, Neuropsychopharmacology.

[2]  D. Lovinger,et al.  Endocannabinoid modulation of dopamine neurotransmission , 2017, Neuropharmacology.

[3]  P. Kalivas,et al.  New vistas on cannabis use disorder , 2017, Neuropharmacology.

[4]  J. Kahn,et al.  Acute effects of synthetic cannabinoids: Update 2015 , 2017, Substance abuse.

[5]  P. Pinton,et al.  Pharmaco‐toxicological effects of the novel third‐generation fluorinate synthetic cannabinoids, 5F‐ADBINACA, AB‐FUBINACA, and STS‐135 in mice. In vitro and in vivo studies , 2017, Human psychopharmacology.

[6]  C. White,et al.  The Pharmacologic and Clinical Effects of Illicit Synthetic Cannabinoids , 2017, Journal of clinical pharmacology.

[7]  C. Trapella,et al.  Synthetic cannabinoid JWH-018 and its halogenated derivatives JWH-018-Cl and JWH-018-Br impair Novel Object Recognition in mice: Behavioral, electrophysiological and neurochemical evidence , 2016, Neuropharmacology.

[8]  J. Kornhuber,et al.  The behavioral profile of spice and synthetic cannabinoids in humans , 2016, Brain Research Bulletin.

[9]  M. A. De Luca,et al.  Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies , 2016, Psychopharmacology.

[10]  K. Varani,et al.  Effect of JWH-250, JWH-073 and their interaction on “tetrad”, sensorimotor, neurological and neurochemical responses in mice , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[11]  M. A. De Luca,et al.  Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135 , 2016, Neuropharmacology.

[12]  M. A. De Luca,et al.  Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants , 2016, Front. Neurosci..

[13]  Z. Cooper Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal , 2016, Current Psychiatry Reports.

[14]  L. Fattore Synthetic Cannabinoids—Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis , 2016, Biological Psychiatry.

[15]  R. Maldonado,et al.  Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ9‐tetrahydrocannabinol , 2016, British journal of pharmacology.

[16]  A. Ennaceur,et al.  Preclinical animal anxiety research – flaws and prejudices , 2016, Pharmacology research & perspectives.

[17]  L. Parsons,et al.  Stimulation of in vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid , 2015, Neuropharmacology.

[18]  C. Trapella,et al.  JWH-018 impairs sensorimotor functions in mice , 2015, Neuroscience.

[19]  K. Varani,et al.  Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice , 2015, Neuropharmacology.

[20]  M. H. Cheng,et al.  Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and Cocaine Binding , 2015, Front. Neurol..

[21]  Renée Kinden,et al.  Cannabinoids & Stress: Impact of HU-210 on behavioral tests of anxiety in acutely stressed mice , 2015, Behavioural Brain Research.

[22]  Abraham Weizman,et al.  Alterations in brain neurotrophic and glial factors following early age chronic methylphenidate and cocaine administration , 2015, Behavioural Brain Research.

[23]  Matt Anderson,et al.  European Monitoring Centre for Drugs and Drug Addiction , 2014 .

[24]  M. Pistis,et al.  Enhanced Endocannabinoid-Mediated Modulation of Rostromedial Tegmental Nucleus Drive onto Dopamine Neurons in Sardinian Alcohol-Preferring Rats , 2014, The Journal of Neuroscience.

[25]  A. Duatti,et al.  Preparation and first biological evaluation of novel Re-188/Tc-99m peptide conjugates with substance-P. , 2014, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[26]  G. Laviola,et al.  A behavioural test battery to investigate tic-like symptoms, stereotypies, attentional capabilities, and spontaneous locomotion in different mouse strains , 2014, Behavioural Brain Research.

[27]  Tracy L. Brewer,et al.  A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. , 2014, Journal for specialists in pediatric nursing : JSPN.

[28]  G. Panagis,et al.  Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity. , 2013, The international journal of neuropsychopharmacology.

[29]  Tony J. Prescott,et al.  Whisker Movements Reveal Spatial Attention: A Unified Computational Model of Active Sensing Control in the Rat , 2013, PLoS Comput. Biol..

[30]  John Q. Wang,et al.  Differential regulation of locomotor activity to acute and chronic cocaine administration by acid-sensing ion channel 1a and 2 in adult mice , 2013, Neuroscience.

[31]  M. Barratt,et al.  Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. , 2013, Drug and alcohol dependence.

[32]  V. Auwärter,et al.  Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. , 2013, Addiction.

[33]  V. Setola,et al.  Neurochemical profiles of some novel psychoactive substances. , 2013, European journal of pharmacology.

[34]  G. Laviola,et al.  Behavioral Responses to Acute and Sub-chronic Administration of the Synthetic Cannabinoid JWH-018 in Adult Mice Prenatally Exposed to Corticosterone , 2013, Neurotoxicity Research.

[35]  B. Lutz,et al.  Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission , 2012, Neuropsychopharmacology.

[36]  V. Pickel,et al.  Cannabinoid modulation of the dopaminergic circuitry: Implications for limbic and striatal output , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[37]  J. Rhodes,et al.  Acute locomotor responses to cocaine in adolescents vs. adults from four divergent inbred mouse strains , 2010, Genes, brain, and behavior.

[38]  K. Fuxe,et al.  Nanomolar concentrations of cocaine enhance D2-like agonist-induced inhibition of the K+-evoked [3H]-dopamine efflux from rat striatal synaptosomes: a novel action of cocaine , 2010, Journal of Neural Transmission.

[39]  J. Javitch,et al.  Syntaxin 1A Interaction with the Dopamine Transporter Promotes Amphetamine-Induced Dopamine Efflux , 2008, Molecular Pharmacology.

[40]  A. Duatti,et al.  Whole-Body Biodistribution and Radiation Dosimetry of the New Cardiac Tracer 99mTc-N-DBODC , 2008, Journal of Nuclear Medicine.

[41]  A. Duatti,et al.  Novel Tc-99m radiotracers for brain imaging , 2007 .

[42]  W. A. Owens,et al.  CB1‐independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum , 2007, Journal of neurochemistry.

[43]  Natalia Auricchio,et al.  CT with a CMOS flat panel detector integrated on the YAP-(S)PET scanner for in vivo small animal imaging , 2007 .

[44]  P. Hof,et al.  A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy , 2005, Neuroscience.

[45]  E Sylvester Vizi,et al.  Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis , 2005, The Journal of Neuroscience.

[46]  M. Koch,et al.  Effects of the cannabinoid receptor agonist win 55,212-2 on operant behavior and locomotor activity in rats , 2005, Pharmacology Biochemistry and Behavior.

[47]  Daniele Lecca,et al.  Dopamine and drug addiction: the nucleus accumbens shell connection , 2004, Neuropharmacology.

[48]  A. Del Guerra,et al.  Performance evaluation of the fully engineered YAP-(S)PET scanner for small animal imaging , 2004, IEEE Transactions on Nuclear Science.

[49]  P. Broderick,et al.  Acute and subacute effects of risperidone and cocaine on accumbens dopamine and serotonin release using in vivo microvoltammetry on line with open-field behavior , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[50]  Sanjiv Sam Gambhir,et al.  AMIDE: a free software tool for multimodality medical image analysis. , 2003, Molecular imaging.

[51]  R. Moratalla,et al.  Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia , 2003, Neuroscience.

[52]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[53]  B. Szabo,et al.  Effects of Cannabinoids on Dopamine Release in the Corpus Striatum and the Nucleus Accumbens In Vitro , 1999, Journal of neurochemistry.

[54]  J. Walker,et al.  Motor actions of cannabinoids in the basal ganglia output nuclei. , 1999, Life sciences.

[55]  M. Christie,et al.  The Anxiogenic-Like and Anxiolytic-Like Effects of MDMA on Mice in the Elevated Plus-Maze A Comparison With Amphetamine , 1999, Pharmacology Biochemistry and Behavior.

[56]  C. Breivogel,et al.  The Functional Neuroanatomy of Brain Cannabinoid Receptors , 1998, Neurobiology of Disease.

[57]  F. Fonseca,et al.  Role of the Endogenous Cannabinoid System in the Regulation of Motor Activity , 1998, Neurobiology of Disease.

[58]  R. Mechoulam,et al.  Biphasic Effects of Anandamide , 1998, Pharmacology Biochemistry and Behavior.

[59]  M. Brecht,et al.  Functional architecture of the mystacial vibrissae , 1997, Behavioural Brain Research.

[60]  G. Laviola,et al.  d-amphetamine conditioned place preference in developing mice: relations with changes in activity and stereotypies. , 1994, Behavioral neuroscience.

[61]  J. Costentin,et al.  Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions , 1994, Behavioural Brain Research.

[62]  P. Broderick In vivo electrochemical studies of gradient effects of (SC) cocaine on dopamine and serotonin release in dorsal striatum of conscious rats , 1993, Pharmacology Biochemistry and Behavior.

[63]  R. Wechsler,et al.  Real time detection of acute (IP) cocaine-enhanced dopamine and serotonin release in ventrolateral nucleus accumbens of the behaving Norway rat , 1993, Pharmacology Biochemistry and Behavior.

[64]  A. Gorman,et al.  Anxiogenic effects of acute and chronic cocaine administration: Neurochemical and behavioral studies , 1992, Pharmacology Biochemistry and Behavior.

[65]  P. Broderick Cocaine: On-line analysis of an accumbens amine neural basis for psychomotor behavior , 1991, Pharmacology Biochemistry and Behavior.

[66]  M. Giordano,et al.  The effects of cocaine on multivariate locomotor behavior and defecation , 1990, Behavioural Brain Research.

[67]  R. Roth,et al.  Cocaine increases extracellular dopamine in rat nucleus accumbens and ventral tegmental area as shown by in vivo microdialysis , 1989, Neuroscience Letters.

[68]  U. Ungerstedt,et al.  Ca2+ dependence of the amphetamine, nomifensine, and Lu 19-005 effect on in vivo dopamine transmission. , 1989, European journal of pharmacology.

[69]  D. Treit,et al.  Thigmotaxis as a test for anxiolytic activity in rats , 1988, Pharmacology Biochemistry and Behavior.

[70]  J. B. Justice,et al.  Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine and benztropine. , 1987, European journal of pharmacology.

[71]  P. Sanberg,et al.  The topography of amphetamine and scopolamine-induced hyperactivity: toward an activity print. , 1987, Behavioral neuroscience.

[72]  R. Wise,et al.  Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. , 1977, Canadian journal of psychology.

[73]  R N Walsh,et al.  The Open-Field Test: a critical review. , 1976, Psychological bulletin.

[74]  S. Snyder,et al.  Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. , 1975, The Journal of pharmacology and experimental therapeutics.

[75]  J. Howes,et al.  The effect of Δ9-tetrahydrocannabinol on the uptake and release of 14C-dopamine from crude striatal synaptosomal preparations , 1974 .

[76]  K. Sharma,et al.  Showcase: Latest dental equipment , 2005, British Dental Journal.

[77]  P. Mariani,et al.  Biodistribution of nanostructured lipid carriers: a tomographic study. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[78]  B. Logan,et al.  Pharmacology, Toxicology, and Adverse Effects of Synthetic Cannabinoid Drugs. , 2014, Forensic science review.

[79]  K. Scherer,et al.  Trends and developments Courants et tendances , 2008 .

[80]  Allan MacKenzie-Graham,et al.  Brain atlases and neuroanatomic imaging. , 2007, Methods in molecular biology.

[81]  J. Avery Critical review. , 2006, The Journal of the Arkansas Medical Society.

[82]  V. Cestari,et al.  D1 and D2 receptor antagonists differently affect cocaine-induced locomotor hyperactivity in the mouse , 2005, Psychopharmacology.

[83]  J. Hallera,et al.  CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents , 2004 .

[84]  S. Kish,et al.  Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. , 1994, Molecular pharmacology.

[85]  M. Kuhar,et al.  Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. , 1990, Life sciences.

[86]  P. Kalivas,et al.  Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens , 1990, Synapse.

[87]  M. Geyer,et al.  Neurochemical mechanisms involved in behavioral effects of amphetamines and related designer drugs. , 1989, NIDA research monograph.

[88]  N. Weiner,et al.  Inhibitory effects of amphetamine on potassium-stimulated release of [3H]dopamine from striatal slices and synaptosomes. , 1987, The Journal of pharmacology and experimental therapeutics.

[89]  J. Howes,et al.  The effect of delta9-tetrahydrocannabinol on the uptake and release of 14C-dopamine from crude striatal synaptosoma; preparations. , 1974, Neuropharmacology.